# Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC

> **NCT06863506** · PHASE2 · RECRUITING · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 78 (estimated)

## Conditions studied

- NSCLC (Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** befotertinib

## Key facts

- **NCT ID:** NCT06863506
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2025-03-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06863506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06863506, "Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06863506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*